Afya (NASDAQ:AFYA) Upgraded at Bank of America

Bank of America upgraded shares of Afya (NASDAQ:AFYA) from a neutral rating to a buy rating in a research report report published on Thursday morning, MarketBeat reports. They currently have $16.00 target price on the stock.

AFYA has been the subject of a number of other reports. Bradesco Corretora upgraded shares of Afya to an “outperform” rating and set a $17.00 price target for the company in a report on Thursday, September 24th. Weiss Ratings lowered Afya from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, July 31st. Wall Street Zen raised Afya from a “hold” rating to a “buy” rating in a research report on Saturday, September 5th. JPMorgan Chase & Co. raised Afya from a “neutral” rating to an “overweight” rating and cut their price objective for the stock from $21.00 to $19.00 in a research report on Wednesday, October 7th. Finally, Zacks Research raised Afya from a “strong sell” rating to a “hold” rating in a report on Monday, October 5th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Afya currently has an average rating of “Hold” and an average target price of $17.00.

Afya Trading Up 2.8%

Shares of AFYA stock opened at $10.45 on Thursday. Afya has a 12 month low of $9.66 and a 12 month high of $16.16. The company has a quick ratio of 2.20, a current ratio of 2.20 and a debt-to-equity ratio of 0.39. The business’s 50 day moving average is $13.63 and its two-hundred day moving average is $14.20. The company has a market cap of $979.37 million, a PE ratio of 6.37, a price-to-earnings-growth ratio of 1.27 and a beta of 0.34.

Afya (NASDAQ:AFYA) last released its quarterly earnings results on Friday, August 14th. The company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.40 by $0.03. The company had revenue of $187.80 million for the quarter, compared to analyst estimates of $189.62 million. Afya had a net margin of 20.55% and a return on equity of 17.58%. Equities analysts predict that Afya will post 1.72 EPS for the current year.

Insiders Place Their Bets

In other Afya news, insider Santos Welder Ferreira sold 4,161 shares of the stock in a transaction on Monday, October 5th. The shares were sold at an average price of $13.30, for a total value of $55,341.30. Following the completion of the sale, the insider directly owned 35,000 shares of the company’s stock, valued at $465,500. This represents a 10.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Afya stock. Public Employees Retirement System of Ohio bought a new stake in Afya Limited (NASDAQ:AFYA) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 4,500 shares of the company’s stock, valued at approximately $67,000. Institutional investors and hedge funds own 88.02% of the company’s stock.

About Afya

Afya Limited is a medical education and digital health company focused on Brazil. Through its educational platform, the company provides undergraduate medical education, medical residency preparation, specialization and continuing medical education programs, and other learning resources for students and physicians.

Afya also offers digital products and services intended to support healthcare professionals throughout their careers. These include clinical content, study tools, telemedicine and practice-management solutions, and subscription-based applications designed to assist physicians with education, clinical decision-making, and patient care.

The company has expanded through the development and acquisition of medical schools, education businesses, and health technology platforms serving different stages of the medical professional lifecycle.